Financière de Tubize SA (TUB.BR)
EUR 138.8
(-0.86%)
EUR 138.8
(-0.86%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.14 Million EUR | -17.62% |
| 2022 | -1.82 Million EUR | -100.48% |
| 2021 | 379.97 Million EUR | 45.62% |
| 2020 | 260.93 Million EUR | 23398.04% |
| 2019 | -1.12 Million EUR | -17.77% |
| 2018 | -951 Thousand EUR | -1.17% |
| 2017 | -940 Thousand EUR | -38.85% |
| 2016 | -677 Thousand EUR | -13.97% |
| 2015 | -594 Thousand EUR | 8.33% |
| 2014 | -648 Thousand EUR | 20.3% |
| 2013 | -813 Thousand EUR | -113.39% |
| 2012 | -381 Thousand EUR | -2.42% |
| 2011 | -372 Thousand EUR | -1.92% |
| 2010 | -365 Thousand EUR | -58.7% |
| 2009 | -230 Thousand EUR | -145.36% |
| 2008 | 507 Thousand EUR | 397.06% |
| 2007 | 102 Thousand EUR | 50.0% |
| 2006 | 68 Thousand EUR | 112.73% |
| 2005 | -534 Thousand EUR | -281.63% |
| 2004 | 294 Thousand EUR | -99.75% |
| 2003 | 118.18 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -878.57 Thousand EUR | 0.0% |
| 2023 Q4 | -900.66 Thousand EUR | 0.0% |
| 2023 Q2 | -993.32 Thousand EUR | 0.0% |
| 2023 FY | -1.89 Million EUR | -3.91% |
| 2022 FY | -1.82 Million EUR | -100.48% |
| 2022 Q2 | -781 Thousand EUR | 0.0% |
| 2022 Q4 | -1.11 Million EUR | 0.0% |
| 2021 Q2 | -508 Thousand EUR | 0.0% |
| 2021 FY | 379.97 Million EUR | 45.62% |
| 2021 Q4 | -389 Thousand EUR | 0.0% |
| 2020 Q4 | -1.64 Million EUR | 0.0% |
| 2020 FY | 260.93 Million EUR | 23398.04% |
| 2020 Q2 | -481 Thousand EUR | 0.0% |
| 2019 FY | -1.12 Million EUR | -17.77% |
| 2019 Q2 | -547 Thousand EUR | 0.0% |
| 2019 Q4 | 136.53 Million EUR | 0.0% |
| 2018 FY | -951 Thousand EUR | -1.17% |
| 2018 Q1 | -237.75 Thousand EUR | 21.27% |
| 2018 Q4 | -307 Thousand EUR | 0.0% |
| 2018 Q2 | -518 Thousand EUR | -117.88% |
| 2017 Q2 | -502 Thousand EUR | -113.62% |
| 2017 FY | -940 Thousand EUR | -38.85% |
| 2017 Q4 | -302 Thousand EUR | 0.0% |
| 2017 Q1 | -235 Thousand EUR | -43.29% |
| 2016 FY | -677 Thousand EUR | -13.97% |
| 2016 Q4 | -164 Thousand EUR | 0.0% |
| 2016 Q2 | -373 Thousand EUR | -120.38% |
| 2016 Q1 | -169.25 Thousand EUR | -28.22% |
| 2015 FY | -594 Thousand EUR | 8.33% |
| 2015 Q3 | -148.5 Thousand EUR | 61.92% |
| 2015 Q4 | -132 Thousand EUR | 11.11% |
| 2015 Q2 | -390 Thousand EUR | -162.63% |
| 2015 Q1 | -148.5 Thousand EUR | -3.85% |
| 2014 Q4 | -143 Thousand EUR | 11.73% |
| 2014 FY | -648 Thousand EUR | 20.3% |
| 2014 Q3 | -162 Thousand EUR | 53.58% |
| 2014 Q1 | -162 Thousand EUR | -28.57% |
| 2014 Q2 | -349 Thousand EUR | -115.43% |
| 2013 Q2 | -464 Thousand EUR | -128.29% |
| 2013 Q1 | -203.25 Thousand EUR | 0.0% |
| 2013 Q4 | -126 Thousand EUR | 38.01% |
| 2013 Q3 | -203.25 Thousand EUR | 56.2% |
| 2013 FY | -813 Thousand EUR | -113.39% |
| 2012 Q1 | -104.5 Thousand EUR | 0.0% |
| 2012 FY | -381 Thousand EUR | -2.42% |
| 2012 Q3 | -104.5 Thousand EUR | 0.0% |
| 2012 Q4 | -203.25 Thousand EUR | -94.5% |
| 2012 Q2 | -104.5 Thousand EUR | 0.0% |
| 2011 Q3 | 17.55 Million EUR | 0.0% |
| 2011 FY | -372 Thousand EUR | -1.92% |
| 2011 Q4 | -104.5 Thousand EUR | -100.6% |
| 2011 Q2 | 17.55 Million EUR | 0.0% |
| 2011 Q1 | 17.55 Million EUR | 0.0% |
| 2010 Q4 | 17.55 Million EUR | 90.43% |
| 2010 Q1 | 9.21 Million EUR | 0.0% |
| 2010 FY | -365 Thousand EUR | -58.7% |
| 2010 Q3 | 9.21 Million EUR | 0.0% |
| 2010 Q2 | 9.21 Million EUR | 0.0% |
| 2009 Q4 | 9.21 Million EUR | -77.43% |
| 2009 Q1 | 40.84 Million EUR | 0.0% |
| 2009 Q2 | 40.84 Million EUR | 0.0% |
| 2009 FY | -230 Thousand EUR | -145.36% |
| 2009 Q3 | 40.84 Million EUR | 0.0% |
| 2008 Q1 | -266.5 Thousand EUR | 0.0% |
| 2008 Q3 | -266.5 Thousand EUR | 0.0% |
| 2008 Q2 | -266.5 Thousand EUR | 0.0% |
| 2008 Q4 | 40.84 Million EUR | 15425.23% |
| 2008 FY | 507 Thousand EUR | 397.06% |
| 2007 Q2 | 10.21 Million EUR | 0.0% |
| 2007 Q4 | -266.5 Thousand EUR | -102.61% |
| 2007 Q1 | 10.21 Million EUR | 0.0% |
| 2007 Q3 | 10.21 Million EUR | 0.0% |
| 2007 FY | 102 Thousand EUR | 50.0% |
| 2006 Q1 | -265.75 Thousand EUR | 0.0% |
| 2006 Q2 | -265.75 Thousand EUR | 0.0% |
| 2006 Q3 | -265.75 Thousand EUR | 0.0% |
| 2006 Q4 | 10.21 Million EUR | 3945.06% |
| 2006 FY | 68 Thousand EUR | 112.73% |
| 2005 FY | -534 Thousand EUR | -281.63% |
| 2005 Q4 | -265.75 Thousand EUR | 24.13% |
| 2005 Q3 | -350.25 Thousand EUR | 0.0% |
| 2005 Q2 | -350.25 Thousand EUR | 0.0% |
| 2005 Q1 | -350.25 Thousand EUR | 0.0% |
| 2004 Q4 | -350.25 Thousand EUR | -285.95% |
| 2004 Q2 | -90.75 Thousand EUR | 0.0% |
| 2004 Q3 | -90.75 Thousand EUR | 0.0% |
| 2004 Q1 | -90.75 Thousand EUR | 0.0% |
| 2004 FY | 294 Thousand EUR | -99.75% |
| 2003 Q3 | 29.54 Million EUR | 0.0% |
| 2003 FY | 118.18 Million EUR | 0.0% |
| 2003 Q2 | 29.54 Million EUR | 0.0% |
| 2003 Q1 | 29.54 Million EUR | 0.0% |
| 2003 Q4 | -90.75 Thousand EUR | -100.31% |
| 2002 Q4 | 29.54 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | 37.164% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 98.317% |
| Adocia SA | -17.62 Million EUR | 87.834% |
| Aelis Farma SA | -6.46 Million EUR | 66.817% |
| Biophytis S.A. | -14.33 Million EUR | 85.042% |
| Advicenne S.A. | -6.45 Million EUR | 66.796% |
| genOway Société anonyme | 2.06 Million EUR | 203.81% |
| IntegraGen SA | -183.77 Thousand EUR | -1066.662% |
| Medesis Pharma S.A. | -4.22 Million EUR | 49.307% |
| Neovacs S.A. | -6.9 Million EUR | 68.962% |
| NFL Biosciences SA | -4.43 Million EUR | 51.608% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -175.491% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | 31.661% |
| Sensorion SA | -22.31 Million EUR | 90.39% |
| Theranexus Société Anonyme | -7.64 Million EUR | 71.951% |
| TME Pharma N.V. | -5.62 Million EUR | 61.878% |
| Valbiotis SA | -7.16 Million EUR | 70.056% |
| TheraVet SA | -2.17 Million EUR | 1.431% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 89.432% |
| argenx SE | -417.15 Million EUR | 99.486% |
| BioSenic S.A. | -7.04 Million EUR | 69.546% |
| Celyad Oncology SA | -8.45 Million EUR | 74.649% |
| DBV Technologies S.A. | -85.24 Million EUR | 97.485% |
| Galapagos NV | -88.26 Million EUR | 97.571% |
| Genfit S.A. | -26.58 Million EUR | 91.934% |
| GeNeuro SA | -14.35 Million EUR | 85.067% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 86.594% |
| Innate Pharma S.A. | -12.66 Million EUR | 83.077% |
| Inventiva S.A. | -102.7 Million EUR | 97.913% |
| MaaT Pharma SA | -19.94 Million EUR | 89.249% |
| MedinCell S.A. | -20.97 Million EUR | 89.779% |
| Nanobiotix S.A. | -26.77 Million EUR | 91.994% |
| Onward Medical N.V. | -35.46 Million EUR | 93.954% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 52.871% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 90.673% |
| Oxurion NV | -12.11 Million EUR | 82.296% |
| Pharming Group N.V. | -4.87 Million EUR | 56.062% |
| Poxel S.A. | -28.76 Million EUR | 92.546% |
| GenSight Biologics S.A. | -29.69 Million EUR | 92.78% |
| Transgene SA | -30.01 Million EUR | 92.856% |
| UCB SA | 604 Million EUR | 100.355% |
| Valneva SE | -82.08 Million EUR | 97.388% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 92.565% |